GlassScriptPhysician profile
Maureen Rafferty
NPI 1043314461
$996.83
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $25.00 · 2022: $245 · 2023: $159 · 2024: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $539.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $252.09 | 2019-2024 | Otezla, Repatha, Prolia |
| Abbott Laboratories | $148.69 | 2022-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $92.90 | 2020-2024 | |
| Nevro Corp. | $70.06 | 2019-2024 | Senza |
| Glaxosmithkline, LLC. | $68.75 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $63.49 | 2023-2024 | Xarelto |
| Abbvie INC. | $42.63 | 2019-2022 | |
| Ucb, INC. | $40.73 | 2024 | Cimzia |
| Otsuka America Pharmaceutical, INC. | $28.81 | 2024 | Jynarque |
| Lilly USA, LLC | $23.78 | 2024 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $23.02 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.38 | 2024 | Jardiance, Synjardy |
| Pfizer INC. | $19.84 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.07 | 2024 | Eliquis |
| Regeneron Healthcare Solutions, INC. | $18.99 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $18.82 | 2022 | |
| Genzyme Corporation | $15.70 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $14.13 | 2019 | |
| Novo Nordisk INC | $13.95 | 2023 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Rafferty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.